CDKN2 (MTS1/p16INK4A) gene alterations in adult T-cell leukemia/lymphoma

被引:9
|
作者
Uchida, T [1 ]
Kinoshita, T [1 ]
Murate, T [1 ]
Saito, H [1 ]
Hotta, T [1 ]
机构
[1] Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 466, Japan
关键词
CDKN2 (MTSl/pl6(INK4A) gene; cell cycle regulator; disease progression; adult T-cell leukemia/lymphoma;
D O I
10.3109/10428199809058379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
p16(INK4A) is a cyclin-dependent kinase inhibitor (CDKI), and regulates the cell cycle negatively. Recently, p16(INK4A) protein was shown to be encoded by the CDKN2 gene, which is identical to multiple tumor suppressor gene 1 (MTS1) on chromosome 9p21, where genetic alterations occur frequently in many malignant tumors. As the loss of p16(INK4A) function by genetic alterations leads to inappropriate progression of the cell cycle, the CDKN2 gene has been investigated intensively as a new candidate tumor suppressor gene in many malignant tumors. Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy associated with human T-cell lymphotrophic virus type 1 (HTLV-1). As the development to ATL is believed to require not only HTLV 1 infection but also accumulation of genetic alterations, we investigated the relationship between alterations in the CDKN2 gene and ATL. Alterations in the CDKN2 gene were detected in approximately 15 to 20% of ATL patients. Interestingly, most of the patients with CDKN2 gene alterations had the aggressive form of ATL. The CDKN2 gene appears to be the major tumor suppressor gene on chromosome 9p21, and alteration in this gene may play an important role during late stages in the transformation process induced by HTLV-1.
引用
收藏
页码:27 / 35
页数:9
相关论文
共 50 条
  • [31] p16 (CDKN2/MTS1) gene deletions are present in prostatic carcinoma in Japanese but not Americans
    Mangold, KA
    Takahashi, H
    Furusato, M
    Boyd, J
    Chandler, FW
    Allsbrook, WC
    [J]. LABORATORY INVESTIGATION, 1996, 74 (01) : 444 - 444
  • [32] p16(MTS-1/CDKN2/INK4a) in cancer progression
    Rocco, JW
    Sidransky, D
    [J]. EXPERIMENTAL CELL RESEARCH, 2001, 264 (01) : 42 - 55
  • [33] MTS1/P16/CDKN2 LESIONS IN PRIMARY GLIOBLASTOMA-MULTIFORME
    MOULTON, T
    SAMARA, G
    CHUNG, WY
    YUAN, L
    DESAI, R
    SISTI, M
    BRUCE, J
    TYCKO, B
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1995, 146 (03): : 613 - 619
  • [34] INVOLVEMENT OF THE CDKN2 (P16INK4/MTS1) GENE IN HUMAN LYMPHOID MALIGNANCIES - HIGH-INCIDENCE OF HOMOZYGOUS DELETIONS IN T-ALL/LBL
    OTSUKI, T
    CLARK, HM
    WELLMANN, A
    JAFFE, ES
    RAFFELD, M
    [J]. BLOOD, 1994, 84 (10) : A438 - A438
  • [35] Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas
    Cohen, JA
    Geradts, J
    [J]. HUMAN PATHOLOGY, 1997, 28 (08) : 893 - 898
  • [36] Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma
    Merbs, SL
    Sidransky, D
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (03) : 779 - 783
  • [37] Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas
    Serrano, J
    Goebel, SU
    Peghini, PL
    Lubensky, IA
    Gibril, F
    Jensen, RT
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11): : 4146 - 4156
  • [38] Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers
    Muzeau, F
    Flejou, JF
    Thomas, G
    Hamelin, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1997, 72 (01) : 27 - 30
  • [39] p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan
    Mangold, KA
    Takahashi, H
    Brandigi, C
    Wada, T
    Wakui, S
    Furusato, M
    Boyd, J
    Chandler, FW
    Allsbrook, WC
    [J]. JOURNAL OF UROLOGY, 1997, 157 (03): : 1117 - 1120
  • [40] Mutations of CDKN2 (MTS1/p16(INK4A)) and MTS2/p15(INK4B) genes in human stomach, hepatocellular, and cholangio-carcinomas
    Jae-Ryong Kim
    Seong-Yong Kim
    Bong-Hwan Lee
    Sang-Woon Kim
    Hong-Jin Kim
    Jung-Hye Kim
    [J]. Experimental & Molecular Medicine, 1997, 29 : 151 - 156